Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of the Neisseria meningitidis Serogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan
暂无分享,去创建一个
R. Rappuoli | K. Mills | R. Sinha | G. Griffin | R. Borrow | P. Heath | C. Cosgrove | E. McNeela | D. Lewis | R. Giemza | Z. Huo | Rafaela Giemza
[1] F. Mahoney,et al. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. , 2005, Vaccine.
[2] E. Miller,et al. Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.
[3] G. Kraal. Chapter 23 – Nasal-Associated Lymphoid Tissue , 2005 .
[4] Elizabeth Miller,et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.
[5] S. Clare,et al. Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin , 2004, Infection and Immunity.
[6] A. Meyerhans,et al. Gut-homing (α4β7+) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors , 2004 .
[7] R. Rappuoli,et al. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. , 2004, The Journal of infectious diseases.
[8] R. Borrow,et al. Assignment of Neisseria meningitidis Serogroups A, C, W135, and Y Anticapsular Total Immunoglobulin G (IgG), IgG1, and IgG2 Concentrations to Reference Sera , 2004, Clinical Diagnostic Laboratory Immunology.
[9] A. Meyerhans,et al. Gut-homing (alpha(4)beta(7)(+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. , 2004, The Journal of general virology.
[10] N. Andrews,et al. Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.
[11] F. Oftung,et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. , 2003, Vaccine.
[12] R. Rappuoli,et al. Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A , 2003, Infection and Immunity.
[13] E. Miller,et al. Impact of meningococcal C conjugate vaccine in the UK. , 2002, Journal of medical microbiology.
[14] P. Riches,et al. Limitations of Pneumovax® as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay , 2002, Annals of clinical biochemistry.
[15] B. Brandt,et al. Immunogenicity and Safety Testing of a Group B Intranasal Meningococcal Native Outer Membrane Vesicle Vaccine , 2002, Infection and Immunity.
[16] D. Goldblatt,et al. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. , 2002, The Journal of infectious diseases.
[17] David N. Taylor,et al. Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults , 2001, Infection and Immunity.
[18] H. Domdey,et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. , 2001, Vaccine.
[19] R. Rappuoli,et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.
[20] M. Roberts,et al. Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens , 2000, Infection and Immunity.
[21] F. Oftung,et al. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. , 2000, Vaccine.
[22] F. Oftung,et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. , 2000, Journal of medical microbiology.
[23] G. Carlone,et al. Elderly immune response to a TI-2 antigen: heavy and light chain use and bactericidal activity to Neisseria meningitidis serogroup C polysaccharide. , 1999, The Journal of infectious diseases.
[24] F. Oftung,et al. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. , 1999, Vaccine.
[25] A. Perkins,et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.
[26] J. Chippaux,et al. Meningococcal immunisation and protection from epidemics , 1998, The Lancet.
[27] J. Holmgren,et al. Differential Kinetics and Distribution of Antibodies in Serum and Nasal and Vaginal Secretions after Nasal and Oral Vaccination of Humans , 1998, Infection and Immunity.
[28] F. Oftung,et al. Intranasal Administration of a Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans , 1998, Infection and Immunity.
[29] J. Holmgren,et al. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina , 1997, Infection and immunity.
[30] J. Lowe,et al. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. , 1997, Journal of pharmaceutical sciences.
[31] S. Gizurarson,et al. Intranasal booster vaccination against diphtheria and tetanus in man. , 1997, Vaccine.
[32] E. Tikhomirov,et al. Meningococcal disease: public health burden and control. , 1997, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.
[33] C. Czerkinsky,et al. Induction of compartmentalized B-cell responses in human tonsils , 1995, Infection and immunity.
[34] J. Biewenga,et al. The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.
[35] M. Corbel,et al. Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141–157 of fragment A , 1990, Epidemiology and Infection.
[36] J. Mcghee,et al. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. , 1990, Journal of immunology.
[37] K. Miyamura,et al. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with the rabbit skin method and practical application for seroepidemiological studies. , 1974, Journal of biological standardization.
[38] K. Miyamura,et al. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. , 1974, Journal of biological standardization.